Clozapine-induced myotoxicity in patients with chronic psychotic disorders

Neurology

Volumn 47, Issue 6, 1996, Pages 1518-1523

  Scelsa, S N ^a,b   Simpson, D M ^a   McQuistion, H L ^a,b   Fineman, A ^a   Ault, K ^a   Reichler, B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALMODULIN INHIBITOR; CHLORPROMAZINE; CLOZAPINE; CREATINE KINASE; NEUROLEPTIC AGENT; PHENOTHIAZINE;

ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG INDUCED DISEASE; ELECTROMYOGRAPHY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MENTAL DISEASE; MUSCLE BIOPSY; MYOPATHY; NERVE CONDUCTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RHABDOMYOLYSIS;

EID: 0029758279     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.6.1518     Document Type: Article

References (42)

1. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324:746-754.
2. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. N Eng J Med 1993;329:162-167.
3. Lieberman JA, Johns CA, Kane JM, et al. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 1988;49:271-277.
4. Anderman B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol 1977;11:199-201.
5. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-371.
6. Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 1989;99:S118-S121.
7. Pope HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986;174:493-495.
8. Muller T, Becher T, Fritz J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988;2:1500.
9. Miller DD, Sharafuddin MJ, Kathol RG. A case of clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 1991;52:99-101.
10. Nopoulos P, Flaum M, Miller DD. Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: clozapine-induced NMS without rigidity. Ann Clin Psychiatry 1990;2: 251-253.
11. Weller M, Kornhuber J. Does clozapine cause neuroleptic malignant syndrome? J Clin Psychiatry 1993;54:70-71.
12. Goates MG, Escobar JI. An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of clozapine rechallenge. J Clin Psychopharmacol 1992;12:139-140.
13. Keshavan MS, Stecker J, Kambhampati RK. Creatine kinase elevations with clozapine. Br J Psychiatry 1994;164:118-120.
14. Kirson JI, McQuistion HL, Pierce DW. Severe elevations in serum creatine kinase associated with clozapine. J Clin Psychopharmacol 1995;15:287-288.
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994:273-315.
16. Klaassen CD. Principles of toxicology. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's: the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:49-61.
17. Kissling WR, Ricker K, Pflughaupt KW, et al. Serum myoglobin in primary and secondary muscle disorders. J Neurol 1981;224:229-233.
18. Meltzer HY, Moline R. Muscle abnormalities in acute psychosis. Arch Gen Psychiatry 1970;23:481-491.
19. Meltzer HY, Engel WK. Histochemical abnormalities of skeletal muscle in acutely psychotic patients. Arch Gen Psychiatry 1970;23:492-502.
20. Fischman DA, Meltzer HY, Poppei RW. Disruption of myofibrils in the skeletal muscle of psychotic patients. Arch Gen Psychiatry 1970;23:503-515.
21. Meltzer HY, McBride E, Poppei RW. Rod (nemaline) bodies in the skeletal muscle of an acutely psychotic patient. Neurology 1973;23:769-780.
22. Meltzer HY, Ross-Stanton J, Schlessinger. Mean serum creatine kinase activity in patients with functional psychoses. Arch Gen Psychiatry 1980;37:650-655.
23. Meltzer HY. Serum creatine phosphokinase in schizophrenia. Am J Psychiatry 1976;133:192-197.
24. Gurrera RJ, Chang SS, Romero J. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry 1992;53:56-62.
25. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-1145.
26. Adityanjee. The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. Br J Psychiatry 1991;158:706-707.
27. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202.
28. Meltzer HY, Crayton JW. Subterminal motor nerve abnormalities in psychotic patients. Nature 1974;249:373-375.
29. Crayton JW, Stalberg E, Hilton-Brown P. The motor unit in psychotic patients: a single fibre EMG study. J Neurol Neurosurg Psychiatry 1977;40:455-463.
30. Brockmoller J, Roots I. Assessment of liver metabolic function. Clin Pharmacokinet 1994;27:216-248.
31. Rudorfer MV. Pharmacokinetics of psychotropic drugs in special populations. J Clin Psychiatry 1993;54(suppl):50-56.
32. Arranz MJ, Dawson E, Shaikh S, et al. Cytochrome P450 2D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 1995;39:417-420.
33. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984-990.
34. Fischer V, Vogels B, Maurer G, Tynes RE. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992;260:1355-1360.
35. 2+ influx. Biochem J 1991;274:193-197.
36. Weiss B, Prozialeck WC, Wallace TL. Commentary: interaction of drugs with calmodulin: biochemical, pharmacological and clinical implications. Biochem Pharmacol 1982;31:2217-2226.
37. Perry SV. Activation of the contractile mechanism by calcium. In: Engel AG, Franzini-Armstrong C, eds. Myology. 2nd ed. New York: McGraw-Hill, 1994:529-549.
38. Wong ET, Cobb C, Umahara MK. Heterogeneity of serum CK activity among racial and gender groups of the population. Am J Clin Pathol 1983;79:582-586.
39. Meltzer HY, Dorus E, Grunhaus L, Davis JM, Belmaker R. Genetic control of human plasma creatine phosphokinase activity. Clin Genet 1978;13:321-326.
40. Dinan TG. Calcium-activated potassium conductance: an alternative to the dopamine hypothesis of neuroleptic action? Br J Psychiatry 1987;151:455-459.
41. Meltzer HY, Mrozak S, Boyer M. Effect of intramuscular injections on serum creatine phosphokinase activity. Am J Med Sci 1970;259:42-48.
42. Thase ME, Shostak M. Rhabdomyolysis complicating rapid intramuscular neuroleptization. J Clin Psychopharmacol 1984;4:46-48.